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Abstract 
α1-adrenoceptors (α1-ARs) and “cannabinoid-like” G Protein Coupled Receptor 55 (GPR55) belong 
to the G-protein coupled receptor (GPCR) family and play a crucial role in regulating prostate 
function. Although physical and functional interactions between the cannabinoid and adrenergic 
systems have been reported, analysis of functional interactions between α1-AR and GPR55 in 
normal and neoplastic prostate has not been reported. Since GPR55 levels are high in rodent 
adrenal gland, we propose a function link between the adrenergic system and GPR55 receptor. 
Confocal Laser Scanning Microscopy (CLSM) was employed to examine the endogenous α1-AR and 
GPR55 expression and their co-localization, expressed as fluorescence, in vitro in human andro-
gen-insensitive PC-3 and androgen-sensitive LNCaP prostatic carcinoma cell lines, using the fluo-
rescent ligands—Syto 62 (nuclear stain), BODIPY FL-Prazosin (QAPB; fluorescent quinazoline α1- 
AR ligand) and Tocriflour (T1117; a novel fluorescent diarylpyrazole cannabinoid/GPR55 ligand). 
Fluorescent ligand binding in untreated PC-3 cells and LNCaP cells and spheroids showed hetero-
geneous expression of both α1-ARs and GPR55. A small proportion of cells had both α1-ARs and 
GPR55 in relatively equal numbers indicating a degree of co-localization. Co-localization of fluo-
rescent ligand binding exhibited a stronger correlation in LNCaP (0.87) as compared to PC-3 (0.63) 
cells. Upregulation of α1-AR was observed in PC-3 cells following chronic doxazosin incubation. 
Robust T1117 binding, suggestive of GPR55 upregulation, was also observed in these cells. The 
presence of subtype-rich cells with a degree of co-localization between α1-ARs and GPR55 indi-
cates a possibility for dimerisation or functional interaction and a new paradigm for functional 
synergism in which interactions may be either between cells or involve converging intracellular 
signaling processes. 
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1. Introduction 
Prostate cancer (PCa) is the most common non-cutaneous male cancer and the second highest cause of cancer- 
related deaths in Western society [1]. PCa mortality results from bone and lymph node metastasis and the pro-
gression from androgen-dependent to androgen-independent PCa cell growth [2]. The disease is heterogeneous 
in terms of grade, oncogene/tumor suppressor gene expression, genetics, and its molecular, cellular and hor-
monal profile is complex [1]. These alterations and heterogeneity result in the failure of androgen ablation ther-
apy and chemotherapy, which are major therapeutic modalities for advanced PCa [3]. Therefore, considerable 
efforts are directed towards developing treatment strategies targeting receptors that are a part of the molecular 
circuitry controlling tumor growth.  
1.1. Adrenoceptor 
In PCa, the involvement of a wide range of G-protein coupled receptors (GPCRs) has been described [4]. The 
α1-adrenoceptors (α1-ARs) are of particular interest given their role in prostate function, and use as a therapeutic 
target. A recent comprehensive review of prostatic α1-ARs outlines the complex signaling pathways and addi-
tional GPCRs that this receptor can interact with [5]. Currently, the recognized subtypes of α1-ARs are α1A, α1B, 
α1D [6]. α1A-AR subtypes are the main prostate receptors and predominate in prostate stroma. α1D-AR subtype is 
also found in the stroma whereas α1B-AR is mainly found in the epithelium [7]. Functional studies suggest a 
predominance of α1-ARs which have low affinity for the quinazoline drug, Prazosin, and these have been 
classed as α1L-AR, a functional phenotype of α1A-adrenoceptor, in mouse prostate [8]. 
The role of α1-ARs in human prostate is undisputed and therefore, is the most commonly targeted GPCR in 
the prostate. The α1-AR antagonists belonging to quinazoline family of drugs have therapeutic benefit in PCa as 
they induce apoptosis in the epithelial and smooth muscle cells of the prostate without affecting their prolifera-
tive capacity [9] [10]. Therapeutically, quinazolines decrease the incidence of PCa by 31.7% [11]. Evidence 
highlights the emerging therapeutic significance of two quinazoline drugs, Terazosin and Doxazosin as anti- 
tumor agents in PCa therapy. Doxazosin mesylate (brand name: Cardura), a subtype non-selective α1-adreno- 
ceptor antagonist, promotes smooth muscle relaxation. Doxazosin has also been documented to induce apoptosis 
and anoikis in PCa cells, both in vitro and in vivo [12]. The apoptotic activity of this quinazoline antagonist is 
independent of: 1) ability to antagonize α1-AR; and 2) the hormone sensitivity of cells (i.e. androgen dependen-
cy) but dependent upon number and distribution of smooth muscle cells in the tissue [9]. It induces apoptosis by 
a) increasing caspase-3 activity in a concentration and time dependent manner which activate intracellular cas-
cade promoting anoikis and subsequently, apoptosis; b) cleavage of focal adhesion kinases (FAK), a non-re- 
ceptor tyrosine kinase mediating cell proliferation and migration, by caspases and c) decreasing Akt phosphory-
lation which has been shown to interfere with the apoptotic action of doxazosin [13] [14]. 
1.2. Endocannabinoids 
Several studies have evaluated the role of the endocannabinoid system, consisting of classic cannabinoid recep-
tors, CB1 and CB2, two endogenous ligands (anandamide and 2-arachidonoylglycerol) and several enzymes re-
quired in their production and degradation, in different PCa tissue/cell lines [15]. High CB1 receptor immuno-
reactivity score in PCa tissue was found to be associated with PCa severity and outcome [16]. Also, CB2 recep-
tor expression was demonstrated in multiple PCacell lines (PC-3, DU-145, LNCaP, CWR22Rv1 and CA-HPV- 
10) [17]-[21]. However, role of a putative cannabinoid receptor GPR55, a 319-amino acid multi-pass membrane 
protein phylogenetically distinct from CB1 and CB2, in tumor progression suggests its importance as a possible 
cancer biomarker. High levels of GPR55 have been associated with aggressive cancers [22] and tumor angioge-
nesis [23]. 
We have previously shown co-localization between T1117, a fluorescent form of the cannabinoid CB1 recep-
tor antagonist AM251, which showed binding affinity for GPR55 [24] and BODIPY FL-Prazosin (QAPB), a 
fluorescent ligand for all α1-AR subtypes [25] in vascular tissue indicating their possible interaction in the car-
diovascular system. Since tissue distribution of GPR55 overlaps significantly with α1-AR in prostate, and 
GPR55 shares similar pharmacology with the classical cannabinoid (CB1) receptors [26], we investigated the 
degree of heterogeneity and possibility of interaction between α1-AR and GPR55 by examining their distribution 
and co-localization in vitro using two commonly used prostate carcinoma cell lines; LNCaP and PC-3. The 
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LNCaP and PC-3 cell lines were selected as they display appropriate cellular characteristics and are widely used 
to model androgen-dependent early stage PCa and androgen-independent later refractory stage disease, respec-
tively. Importantly, our findings provide preliminary evidence of co-localization and possible interaction be-
tween α1-AR and GPR55 and its physiological importance in neoplastic prostatic cell in vitro which has never 
been studied prior to this study. 
2. Materials and Methods 
2.1. Materials 
Stock concentrations of fluorescent ligands were dissolved in dimethyl sulphoxide (DMSO), and diluted in dis-
tilled water as required. Ligands were obtained from the following sources: BODIPY FL-Prazosin (QAPB) and 
Syto 62 from Invitrogen (Invitrogen Ltd., Paisley, UK); Tocrifluor T1117 (N-(piperidin-1-yl)-5-(4-(4-(3-(5- 
carboxamidotetramethylrhodaminyl) propyl)) phenyl)-1-(2,4-dicholrophenyl)-4-methyl-1H pyrazole-3-carbox- 
amide) from Tocris (Bristol, UK) and Doxazosin from Pfizer (Sandwich, UK). 
2.2. Cell Culture 
The human androgen-insensitive, PC-3 (ATCC: CRL-1435) and androgen-sensitive, LNCaP (ATCC: CRL-1740) 
prostatic carcinoma cell lines were obtained from American Type Culture Collection repository. Cells were cul-
tured in the appropriate media recommended by the supplier supplemented with 10% Fetal Bovine Serum (FBS), 
Penicillin-Streptomycin (Pen-Strep) and L-Glutamine in a humidified incubator at 37˚C, 95% O2 and 5% CO2 
until confluent. Upon attaining confluence, the cells were trypsinized and rinsed in media and PBS. Subse-
quently, cells were re-suspended and plated to glass coverslips 24 hours before use. 
2.3. Confocal Analysis 
BODIPY FL-Prazosin (QAPB, 0.1 μM) and Tocriflour (T1117, 0.1 μM) were applied in combination to deter-
mine the receptor expression and co-localization in a) control untreated PC-3 and LNCaP cells and LNCaP-  
derived spheroids (24 hours) and b) PC-3 cells under chronic doxazosin treatment (6 weeks; 1 μM) allowed to 
regrow in drug-free media (2 weeks). Incubation media also included a fluorescent nuclear stain Syto 62 (1 
μg/ml). Cell images are representative of at least three independent experiments in all cases. 
2.4. Microscopic Examination 
Cells were imaged using a Bio-Rad Radiance 2100 Confocal Laser Scanning Microscope (CLSM) using either 
an oil immersion lens 20× (NA 0.75) or 40× objective (NA 1.0). The CLSM was fitted with an argon ion, Green 
Helium Neon (HeNe) and red diode laser. In all comparative studies, laser intensity and photomultiplier tube 
(PMT) settings were identical. Fluorescent ligands were imaged as follows: QAPB (ex 488 nm, em 515 nm); 
T1117 (ex 543 nm, em 590 nm) and Syto 62 (ex 637 nm, em 660 nm). Multi-channel images are displayed as 
merged channels. Detailed analysis methods have previously been published [27]. 
2.5. Data Analysis 
Data was collected, recorded and quantified using ImageJ 1.44p. Co-localization was quantified using the JA-
CoP plugin for ImageJ and expressed as a Pearsons Correlation between two fluorophores generated from n = 4 
for PC-3 cells and n = 5 for LNCaP cells. Graphs were drawn using GraphPad PRISM 5.0. Data was expressed 
as mean ± SEM (Standard Error Mean) of at least 3 independent experiments. Statistical tests such as students 
T-tests were carried out and significance was defined as P < 0.05. 
3. Results 
3.1. Co-Localization of Adrenergic and Cannabinoid Binding Sites in Prostate Cancer Cells 
Figure 1 shows the binding pattern of QAPB and T1117 in PC-3 and LNCaP cells (control). In control cell pop-
ulation, heterogeneity extended to the expression of both α1-ARs and GPR55. A spectrum of phenotypes was 
observed within the cell population, from those expressing predominantly α1-AR to those harboring predomi- 
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Figure 1. Fluorescent ligand binding and co-localization in PC-3 and LNCaP 
cells and LNCaP-derived spheroids. (a) Confocal scan of LNCaP cells after in-
cubation with QAPB and fluorescent cannabinoid ligand T1117 (both 0.1 µM) 
showing a combination of cells expressing α1-AR (green), GPR55 (red) or both 
in relatively equal amounts (yellow; red arrow). Inset: LNCaP cells showing 
high GPR55 concentration (red fluorescence; white arrow) within the cell pro- 
cesses; (b) LNCaP-derived spheroids showing similar heterogeneity in receptor 
expression with certain areas showing co-localization of α1-AR and GPR55 
(dotted arrow); (c) Confocal images of PC-3 cells showing α1-AR positive cells 
(QAPB binding-induced green fluorescence) and GPR55 positive cells (T1117 
binding-induced red fluorescence) (inset); (d) Arrow indicates overlapping re-
gions (yellow) of receptor location suggesting a degree of co-localization of 
α1-ARs and GPR55. Nuclei stained with Syto 62 (1 µg/ml). Calibration bar ((a) 
and (c)) indicates 20 microns and for (d) indicates 15 microns.                          
 
nantly GPR55 (Figure 1(c)). Importantly, it was apparent that PC-3 cells do not simply express α1-ARs and 
GPR55 in equal proportions. A small proportion of cells had both α1-ARs and GPR55 in relatively equal num-
bers reflected by the yellow fluorescence indicating a degree of co-localization of QAPB and T1117 (Figure 
1(d)). LNCaP cells (in some but not all) (Figure 1(a)) and spheroids (Figure 1(b)) also demonstrated clear de-
gree of co-localization between α1-AR and GPR55. Co-localization (correlation analysis) of QAPB and T1117 
binding revealed a stronger correlation in LNCaP (0.87 ± 0.03) cells vs PC-3 (0.63 ± 0.02) cells. Interestingly, 
T1117 binding was always associated with the long processes and cell tips of LNCaP cells (Figure 1(a)). 
3.2. Chronic Doxazosin Treatment Elicits Upregulation of Intracellular α1-AR and GPR55  
Expression, Accompanied by Stimulated Growth of PC-3 Cells 
The even distribution of binding sites, in certain areas and apparent co-localization of QAPB and T1117 in con-
trol PC-3 cells suggested co-expression and possibility of strong physical/functional association between the two 
receptors. To determine whether the functional antagonism of α1-AR might result in altered GPR55 expression, 
ligand binding studies were performed in cells that received 1 µM doxazosin treatment for 6 weeks and returned 
to drug-free media for 2 weeks. The QAPB and T1117-binding induced fluorescence were determined in dox-
azosin-treated PC-3 cells normalized against fluorescence seen in untreated cells. Chronic administration of 
doxazosin resulted in significant (P < 0.05) increase in the fluorescence induced by QAPB binding suggesting 
upregulation in α1-AR (Figure 2(a)). T1117-binding induced fluorescence was significantly higher (P < 0.01) 
following chronic treatment with the α1-antagonist (Figure 2(b)). Sample cells are shown for comparison 
(Figure 2(c), Figure 2(d)). 
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Figure 2. Chronic doxazosin treatment causes upregulation of α1-AR and GPR55 expression. (a) Quantitative fluorescence 
measurement of QAPB binding in the presence and absence of doxazosin; (b) Analysis of GPR55 expression determined by 
T1117 fluorescence in PC-3 cells showing upregulation after chronic doxazosin treatment. As a positive control, PC-3 cells 
showing normal growth mechanisms were used. Results are expressed as mean ± SEM. *P < 0.05, **P < 0.01. (c)-(d) Con-
focal images of PC-3 cells before (c) and after (d) chronic doxazosin treatment (1 µM, 6 weeks). A predominance of intra-
cellular GPR55 was observed in response to chronic administration of doxazosin. Each image is a representative of those 
generated from three independent experiments. (Scale bar 20 microns).                                              
4. Discussion 
In recent years, a wealth of information describing the molecular mechanics of GPCR cycle involving agonist 
activation, internalization, downregulation and sequestration have been obtained. In addition, significant amount 
of evidence has highlighted the importance of GPCR dimerisation and co-localization that may alter receptor 
function, pharmacology or regulatory properties [28]. However, heterodimerisation dynamics and its generality 
in controlling receptor expression are not widely explored. Fluorescent ligand binding in vitro in PC-3 and 
LNCaP cells and LNCaP-derived spheroids demonstrated clear degree of co-localization (in some but not all 
cells) between α1-AR and GPR55. Homodimerisation and more selective heterodimerisation between individual 
α1-AR subtypes have been reported [29]. Assays showing functional interactions between cannabinoid and 
adrenoceptor ligands have, in fact, confirmed that adrenoceptor heterodimerisation may extend beyond αα and 
αβ interactions [24]. Although the resolution of current fluorescence-based study was insufficient to confirm the 
existence of α1-AR and GPR55 heterodimer, it does indicate their co-localization which is a pre-requisite of di-
merization. In addition, evidence from recent molecular pharmacological studies has shown that co-expressed 
receptors can interact [26] [30] [31]. It can be hypothesized that co-localized α1-ARs and cannabinoid together 
potentiate the action of neurotransmitters in the prostate since the autonomic nervous system plays an important 
role in prostatic functions [32]. The co-localization of α1-ARs and GPR55 suggest a new paradigm for synerg-
ism in which interactions may be either between cells or involve converging intracellular signaling processes.  
In PCa cells, fluorescent ligand binding studies showed binding sites for both T1117 and QAPB in different 
cellular locations (Figure 1). The binding of QAPB appeared to be more punctuate, both on the cell surface and 
intracellularly whereas binding sites for T1117 were more diffuse as seen earlier from the studies on vascular 
endothelium [24]. This pattern of binding allowed the classification of “subtype-rich” cells which could be 
classed as either expressing predominantly α1-AR or predominantly GPR55. The presence of ‘subtype-rich’ cells 
was also observed in PC-3 cells. The significance of this is currently unknown, but it suggests that a subpopula-
tion of cells have a preferred receptor expression profile in respect of GPCR’s. 
Upregulation of intracellular α1-AR observed in PC-3 cells following removal of chronic α1-AR antagonism 
can be considered an adaptive response to chronic administration of doxazosin. This adaptive change may ma-
nifest as withdrawal response after long-term α1-AR antagonist use and can explain “α1-AR blocker withdrawal 
syndrome” as an aftermath of chronic stimulation of α1-AR. Aarons et al. (1980) have already reported this 
common outcome of an adaptive response to long-term β-AR antagonist use via upregulation of tissue β-ARs 
[33]. Although chronic doxazosin treatment has shown to alter α1-AR properties in rat prostate [34] [35], to our 
knowledge, there is no report of withdrawal response, via α1-AR upregulation, due to chronic administration of 
doxazosin in PCa cells.  
In the present study, novel interaction between α1-AR and GPR55 was identified in vitro in control untreated 
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and doxazosin-treated PC-3 cells. The apparently high expression of intracellular α1-AR in PC-3 cells showed 
that chronic doxazosin-induced response had an α1-AR component. This was expected; intriguingly, robust 
intracellular T1117 binding-fluorescence suggestive of GPR55 upregulation was also observed in these cells. 
This suggests that co-expression of α1-AR tempered the activity of GPR55 resulting in a dramatic increase in its 
intracellular expression in heterologous cells. It is possible that functional and perhaps physical association with 
α1-AR leads to changes in the localization of GPR55 to “active” areas in the intracellular compartment of a cell 
enriched with signaling molecules. The pre-requisite of this event is that the two receptors should be in close 
proximity, influencing their ability to transduce signals. Our co-localization study supports such a notion. In ad-
dition, our observation that PC-3 cells, high in GPR55, grow at a furious rate when returned to drug-free media 
(data not shown) supports our hypothesis that in a clinical setting, removal of α1-antagonism and the resultant 
stimulation of α1-AR may allow lysophosphotidylinositol (LPI), an endogenous natural ligand for GPR55 syn-
thesized intracellularly from membrane phosphoinositols by phospholipase A2 (PLA2), formation via activation 
of PLA(2) to stimulate GPR55-mediated accelerated proliferation. A link between α1-AR stimulation and acti-
vation of PLA(2) has been reported [36] and if this could be demonstrated in prostatic smooth muscle then we 
would have a direct link between α1-AR stimulation and LPI production. The growth aspect is further substan-
tiated by our observation of high levels of T1117 binding sites in the long processes of LNCaP cells. 
It therefore is plausible that complex functional interaction between α1-AR and GPR55 exist whereby α1-AR 
antagonism directly affects GPR55 functionality by overexpression after chronic doxazosin treatment to support 
tumorigenesis by promoting cell growth and drug resistance. Therefore, the α1-ARs\GPR55 ratio could identify 
the metastatic prognosis of PCa cells and may serve as a useful biomarker or predictor of metastatic PCa. If our 
hypothesis is correct, then using carefully constructed, stable, non-toxic fluorescent ligands for the receptors, the 
number of ‘hot’ cells can be determined in a biopsy by clinicians/uropathologists to monitor the efficacy of anti- 
cancer therapy which the individual is undergoing and gauge the potential/progression to aggressive PCa. These 
results present both α1-ARs and GPR55 and catecholamines as potentially significant targets for specific thera-
peutic modalities for treating PCa. 
5. Conclusion 
The present study suggested an interaction between α1-AR and GPR55 via co-localization/dimerization provid-
ing rationale for further studies on mechanisms of cross talk between different subfamilies of GPCRs. These re-
sults open a new avenue of research oriented on delineating direct physical and functional interactions between 
the cannabinoid and adrenergic systems that were primarily attributed to only CB1 receptor mediated presynap-
tic inhibition of noradrenergic transmission [37]-[40]. We suggest, therefore, in the light of our findings and the 
wide, overlapping distribution of α1-AR and GPR55, re-evaluation of interactions between adrenergic and 
GPR55 systems in cells and tissues that co-express both using higher resolution techniques with fluorescent li-
gands. In addition, our finding that the α1-AR antagonist doxazosin alters GPR55 receptor number in cells en-
dogenously expressing both α1-AR and GPR55 needs to be studied in vivo due to the potential clinical signific-
ance of doxazosin in suppressing prostate tumourigenicity [6]. The recent observation that GPR55 is expressed 
in PCa cell line [41], suggests that some of the anti-tumor effects of α1-AR antagonist [6] may be the result of 
indirect action on GPR55 in addition to the blockade of α1-AR. However, the unexpected, novel “GPR55” phe-
nomenon finding, possibly conferring the properties of tumor growth and drug resistance, demonstrates the sig-
nificant impact of α1-AR antagonists, particularly, doxazosin, in prostate carcinogenesis. To our knowledge, the 
current study in PC-3 cells is the first demonstration that chronic doxazosin treatment affects GPR55 expression. 
Since GPR55 has emerged as a lipid-sensitive modulator of oncogenesis, undoubtedly, pharmacology of LPI- 
GPR55 autocrine signaling system warrants focused research to develop novel therapeutics targeting the protein 
or its ligand for the purposes of inhibiting cancer growth and limit the risk of metastases. Moreover, studies need 
to be designed to investigate any association between GPR55 expression and other membrane receptors as well 
as with cancer remission, relapse or resistance following treatment with various chemotherapeutic inhibitory 
agents. 
References 
[1] Russell, P.J. and Kingsley, E.A. (2003) Human Prostate Cancer Cell Lines. Methods in Molecular Medicine Prostate 
Cancer Methods and Protocols, 81, 21-39. http://dx.doi.org/10.1385/1-59259-372-0:21 
K. C. Patil et al. 
 
 218 
[2] Isaacs, J.T. (1994) The Role of Androgens in Prostatic Cancer. Vitamins & Hormones, 49, 433-502. 
http://dx.doi.org/10.1016/S0083-6729(08)61152-8 
[3] Crawford, E.D., Eisenberger, M.A., McLeod, D.C., Spaulding, J., Benson, R., Dorr, F.A., Blumenstein, B.A., Davis, 
M.A. and Goodman, P.J. (1989) A Controlled Randomized Trial of Leuprolide with and without Flutamide in Prostatic 
Cancer. New England Journal of Medicine, 321, 419-424. http://dx.doi.org/10.1056/NEJM198908173210702 
[4] Daaka, Y.G. (2004) Proteins in Cancer: The Prostate Cancer Paradigm. Sci STKE, 216, 1-10.  
[5] Hennenberg, M., Stief, C.G. and Gratzke, C. (2014) Prostatic a1-adrenoceptors: New Concepts of Function, Regulation, 
and Intracellular Signaling. Neurology & Urodynamics, 33, 1074-1085. http://dx.doi.org/10.1002/nau.22467 
[6] Kyprianou, N., Chon, J. and Benning, C.M. (2000) Effects of Alpha1-Adrenoceptor (α1-AR) Antagonists on Cell Pro-
liferation and Apoptosis in the Prostate: Therapeutic Implications in Prostatic Disease. The Prostate Supplement, 9, 
42-46. http://dx.doi.org/10.1002/1097-0045(2000)45:9+<42::AID-PROS9>3.0.CO;2-U 
[7] Desiniotis, A. and Kyprianou, N. (2011) Advances in the Design and Synthesis of Prazosin Derivatives over the Last 
Ten Years. Expert Opinion on Therapeutic Targets, 15, 1405-1418. http://dx.doi.org/10.1517/14728222.2011.641534 
[8] Gray, K., Short, J. and Ventura, S. (2008) The α1A-Adrenoceptor Gene Is Required for the α1L-Adrenoceptor-Medi- 
ated Response in Isolated Preparations of the Mouse Prostate. British Journal of Pharmacology, 155, 103-109.  
http://dx.doi.org/10.1038/bjp.2008.245 
[9] Kyprianou, N., Litvak, J., Alexander, R.B., Borkowski, A. and Jacobs, S.C. (1998) Induction of Prostate Apoptosis by 
Doxazosin. Journal of Urology, 159, 1810-1815. http://dx.doi.org/10.1016/S0022-5347(01)63162-8 
[10] Chon, J., Isaacs, J.T., Borkowski, A., Partin, A.W., Jacobs, S.C. and Kyprianou, N. (1999) α-1 Adrenoceptor Antagon-
ists Terazosin and Doxazosin Induce Prostate Apoptosis without Affecting Cell Proliferation in Patients with Benign 
Prostatic Hyperplasia. Journal of Urology, 161, 2002-2008. http://dx.doi.org/10.1016/S0022-5347(05)68873-8 
[11] Harris, A.M., Warner, B.W., Wilson, J.M., Becker, A., Rowland, R.G., Conner, W., Lane, M., Kimbler, K., Durbin, 
E.B., Baron, A.T. and Kyprianou, N. (2007) Effect of α1-Adrenoceptor Antagonist Exposure on Prostate Cancer Inci-
dence: An Observational Cohort Study. The Journal of Urology, 178, 2176-2180. 
http://dx.doi.org/10.1016/j.juro.2007.06.043 
[12] Kyprianou, N. (2003) Doxazosin and Terazosin Suppress Prostate Growth by Inducing Apoptosis: Clinical Signific-
ance. The Journal of Urology, 169, 1520-1525. http://dx.doi.org/10.1097/01.ju.0000033280.29453.72 
[13] Walden, P.D., Globina, Y. and Nieder, A. (2004) Induction of Anoikis by Doxazosin in Prostate Cancer Cells Is Asso-
ciated with Activation of Caspase-3 and a Reduction of Focal Adhesion Kinase. Urological Research, 32, 261-265. 
http://dx.doi.org/10.1007/s00240-003-0365-7 
[14] Garrison, J. and Kyprianou, N. (2006) Doxazosin Induces Apoptosis of Benign and Malignant Prostate Cells via a 
Death Receptor-Mediated Pathway. Cancer Research, 66, 464-472. 
http://dx.doi.org/10.1158/0008-5472.CAN-05-2039 
[15] Henstridge, C.M. (2012) Off-Target Cannabinoid Effects Mediated by GPR55. Pharmacology, 89, 179-187. 
http://dx.doi.org/10.1159/000336872 
[16] Chung, S.C., Hammarsten, P., Josefsson, A., Stattin, P., Granfors, T. and Egevad, L. (2009) A High Cannabinoid CB1 
Receptor Immune-Reactivity Is Associated with Disease Severity and Outcome in Prostate Cancer. European Journal 
of Cancer, 45, 174-182. http://dx.doi.org/10.1016/j.ejca.2008.10.010 
[17] Melck, D., Rueda, D., Galve-Roperh, I., De Petrocellis, L., Guzmán, M. and Di Marzo, V. (1999) Involvement of the 
cAMP/Protein Kinase A Pathway and of Mitogen-Activated Protein Kinase in the Anti-Proliferative Effects of Anan-
damide in Human Breast Cancer Cells. FEBS Letters, 463, 235-240. http://dx.doi.org/10.1016/S0014-5793(99)01639-7 
[18] Sánchez, M.G., Ruiz-Llorente, L., Sánchez, A.M. and Díaz-Laviada, I. (2003) Activation of Phosphoinositide 
3-Kinase/PKB Pathway by CB1 and CB2 Cannabinoid Receptors Expressed in Prostate PC-3 Cells: Involvement in 
Raf-1 Stimulation and NGF Induction. Cellular Signalling, 15, 851-859. 
http://dx.doi.org/10.1016/S0898-6568(03)00036-6 
[19] Nithipatikom, K., Endsley, M.P., Isbell, M.A., Falck, J.R., Iwamoto, Y., Hillard, C.J. and Campbell, W. (2004) 
2-Arachidonoylglycerol: A Novel Inhibitor of Androgen-Independent Prostate Cancer Cell Invasion. Cancer Research, 
64, 8826-8830. http://dx.doi.org/10.1158/0008-5472.CAN-04-3136 
[20] Sarfaraz, S., Afaq, F., Adhami, V.M. and Mukhtar, H. (2005) Cannabinoid Receptor as a Novel Target for the Treat-
ment of Prostate Cancer. Cancer Research, 65, 1635-1641. http://dx.doi.org/10.1158/0008-5472.CAN-04-3410 
[21] Brown, I., Cascio, M.G., Wahle, K.W., Smoum, R., Mechoulam, R. and Ross, R.A. (2010) Cannabinoid Recep-
tor-Dependent and -Independent Anti-Proliferative Effects of Omega-3 Ethanolamides in Androgen Receptor-Positive 
and -Negative Prostate Cancer Cell Lines. Carcinogenesis, 31, 1584-1591. http://dx.doi.org/10.1093/carcin/bgq151 
[22] Andradas, C., Caffarel, M.M., Perez-Gomez, E., Salazar, M., Lorente, M., Velasco, G., Guzman, M. and Sanchez, M. 
K. C. Patil et al. 
 
 219 
(2011) The Orphan G Protein-Coupled Receptor GPR55 Promotes Cancer Cell Proliferation via ERK. Oncogene, 30, 
245-252. http://dx.doi.org/10.1038/onc.2010.402 
[23] Bondarenko, A., Waldeck-Weiermair, M., Naghdi, S., Poteser, M., Malli, R. and Graier, W. (2010) GPR55-Dependent 
and -Independent Ion Signaling in Response to Lysophosphatidylinositol in Endothelial Cells. British Journal of 
Pharmacology, 161, 308-320. http://dx.doi.org/10.1111/j.1476-5381.2010.00744.x 
[24] Daly, C.J., Ross, R.A., Whyte, J., Henstridge, C.M., Irving, A.J. and McGrath, J.C. (2010) Fluorescent Ligand Binding 
Reveals Heterogeneous Distribution of Adrenoceptors and “Cannabinoid-Like” Receptors in Small Arteries. British 
Journal of Pharmacology, 159, 787-796. http://dx.doi.org/10.1111/j.1476-5381.2009.00608.x 
[25] Daly, C.J., Milligan, C.M., Milligan, G., Mackenzie, J.F. and Mcgrath, J.C. (1998) Cellular Localization and Pharma-
cological Characterization of Functioning Alpha-1 Adrenoceptors by Fluorescent Ligand Binding and Image Analysis 
Reveals Identical Binding Properties of Clustered and Diffuse Populations of Receptors. The Journal of Pharmacology 
and Experimental Therapeutics, 286, 984-990. 
[26] Hudson, B.D., Hébert, T.E. and Kelly, M. (2010) Physical and Functional Interactions between CB1 Cannabinoid Re-
ceptors and β2-Adrenocepors. British Journal of Pharmacology, 160, 627-642. 
http://dx.doi.org/10.1111/j.1476-5381.2010.00681.x 
[27] Daly, C.J. and McGrath, J.C. (2011) Previously Unsuspected Widespread Cellular and Tissue Distribution of Be-
ta-Adrenoceptors and Its Relevance to Drug Action. Trends in Pharmacological Sciences, 32, 219-226. 
http://dx.doi.org/10.1016/j.tips.2011.02.008 
[28] Angers, S., Salapour, A. and Bouvier, M. (2002) Dimerization: An Emerging Concept for G Protein—Coupled Recep-
tor Ontogeny and Function. Annual Review of Pharmacology and Toxicology, 42, 409-435. 
http://dx.doi.org/10.1146/annurev.pharmtox.42.091701.082314 
[29] Milligan, G., Pediani, J., Fidock, M. and López-Giménez, J.F. (2004) Dimerization of Alpha1-Adrenoceptors. Bio-
chemical Society Transactions, 32, 847-850. 
[30] Uberti, M., Hague, C., Oller, H., Minneman, K. and Hall, R. (2005) Heterodimerisation with β2-Adrenergic Receptors 
Promotes Surface Expression and Functional Activity of α1D-Adrenergic Receptors. Journal of Pharmacology and Ex-
perimental Therapeutics, 313, 16-23. http://dx.doi.org/10.1124/jpet.104.079541 
[31] Copik, A.J., Ma, C., Kosaka, A., Sahdeo, S., Trane, A., Ho, H., Dietrich, P.S., Yu, H., Ford, A.P., Button, D. and Milla, 
M.E. (2009) Facilitatory Interplay in α1a and β2 Adrenoceptor Function Reveals a Non-Gq Signaling Mode: Implica-
tions for Diversification of Intracellular Signal Transduction. Molecular Pharmacology, 75, 713-728. 
http://dx.doi.org/10.1124/mol.108.050765 
[32] Pennefather, J.N., Lau, W.A., Mitchelson, F. and Ventura, S. (2000) The Autonomic and Sensory Innervation of the 
Smooth Muscle of the Prostate Gland: A Review of Pharmacological and Histological Studies. Journal of Autonomic 
Pharmacology, 20, 193-206. http://dx.doi.org/10.1046/j.1365-2680.2000.00195.x 
[33] Aarons, R.D., Nies, A.S., Gal, J., Hegstrand, L.R. and Molinoff, P.B. (1980) Elevation of Beta-Adrenergic Receptor 
Density in Human Lymphocytes after Propranolol Administration. Journal of Clinical Investigation, 65, 949-957. 
http://dx.doi.org/10.1172/JCI109781 
[34] Foster Jr., H.E., Yono, M., Shin, D., Takahashi, W., Pouresmail, M., Afiatpour, P. and Latifpour, J. (2004) Effects of 
Chronic Administration of Doxazosin on α1-Adrenoceptors in the Rat Prostate. The Journal of Urology, 172, 2465- 
2470. http://dx.doi.org/10.1097/01.ju.0000138475.89790.88 
[35] Yono, M., Poster Jr., H.E., Shin, D., Takahashi, W., Pouresmail, M. and Latifpour, J. (2004) Doxazosin Treatment 
Causes Differential Alterations of α1-Adrenoceptor Subtypes in the Rat Kidney, Heart and Aorta. Life Sciences, 75, 
2605-2614. http://dx.doi.org/10.1016/j.lfs.2004.08.001 
[36] Kreda, S.M., Sumner, M., Fillo, S., Ribeiro, C.M., Luo, G.X., Xie, W., Daniel, K.W., Shears, S., Collins, S. and Wetsel, 
W.C. (2001) α1-Adrenergic Receptors Mediate LH-Releasing Hormone Secretion through Phospholipases C and A2 in 
Immortalized Hypothalamic Neurons. Endocrinology, 142, 4839-4851. 
[37] Schlicker, E., Timm, J., Zentner, J. and Gothert, M. (1997) Cannabinoid CB1 Receptor-Mediated Inhibition of Nora-
drenaline Release in the Human and Guinea-Pig Hippocampus. Naunyn-Schmiedeberg’s Archives of Pharmacology, 
356, 583-589. http://dx.doi.org/10.1007/PL00005093 
[38] Schultheiss, T., Flau, K., Kathmann, M., Gothert, M. and Schlicker, E. (2005) Cannabinoid CB1 Receptor-Mediated 
Inhibition of Noradrenaline Release in Guinea-Pig Vessels, but Not in Rat and Mouse Aorta. Naunyn-Schmiedeberg’s 
Archives of Pharmacology, 372, 139-146. http://dx.doi.org/10.1007/s00210-005-0007-4 
[39] Pakdeechote, P., Dunn, W.R. and Ralevic, V. (2007) Cannabinoids Inhibit Noradrenergic and Purinergic Sympathetic 
Cotransmission in the Rat Isolated Mesenteric Arterial Bed. British Journal of Pharmacology, 152, 725-733. 
http://dx.doi.org/10.1038/sj.bjp.0707397 
[40] Tam, J., Trembovler, V., Di Marzo, V., Petrosino, S., Leo, G., Alexandrovich, A., Regev, E., Casap, N., Shteyer, A., 
K. C. Patil et al. 
 
 220 
Ledent, C., Karsak, M., Zimmer, A., Mechoulam, R., Yirmiya, R., Shohami, E. and Bab, I. (2008) The Cannabinoid 
CB1 Receptor Regulates Bone Formation by Modulating Adrenergic Signaling. The FASEB Journal, 22, 285-294. 
http://dx.doi.org/10.1096/fj.06-7957com 
[41] Pineiro, R., Maffucci, T. and Falasca, M. (2011) The Putative Cannabinoid Receptor GPR55 Defines a Novel Auto-
crine Loop in Cancer Cell Proliferation. Oncogene, 30, 142-152. http://dx.doi.org/10.1038/onc.2010.417 
